Dec 11, 2019 · We thank the patients who participated in this trial and their families, as well as the investigators and staff at all HER2CLIMB clinical sites; the members of the independent data …

Aug 14, 2023 · A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

Learn more about the HER2CLIMB clinical trial including the trial design, endpoints and more. Read full indication and important safety information.

May 31, 2023 · HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.. If …

Patients and methods: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with …

Current primary analysis of phase III HER2CLIMB-02 trial evaluated efficacy and safety of tucatinib + T-DM1 in patients with previously treated HER2-positive LA/MBC8

Trial design HER2CLIMB-04 (NCT04539938) is a single-arm, open-label phase 2 trial evaluating the efficacy and safety of TUC + T-DXd in pts with HER2+ unresectable, locally advanced or …

Oct 17, 2025 · Breast Cancer experts Dr. Erika Hamilton and Dr. Kate Lathrop discuss the recent announcement of results from the HER2CLIMB-05 Trial from PIK3CA Wild-Type Cohort in the …

May 2, 2024 · This is the first report of HER2CLIMB-02 (NCT03975647), a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of tucatinib …

Nov 1, 2023 · The regulatory recommendations are based on data from the HER2CLIMB trial, which randomized patients with metastatic BC to receive trastuzumab and capecitabine with …